Cost-effectiveness of Adjuvant Pembrolizumab in Resected Localized Renal Cell Carcinoma in Sri Lanka: A decision-analytic Markov model

Clinical Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles